tapentadol (CG5503) Extended Release (ER)

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Low Back PainOsteoarthritisPain

Phase 3

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

CompletedNCT00487435

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Low Back Pain, Osteoarthritis, Pain

Start: 2007-06-30End: 2009-06-30Updated: 2014-05-09

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

CompletedNCT00594516

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Low Back Pain

Start: 2007-12-31End: 2008-05-31Updated: 2015-04-15

Related Papers

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.

2015-10-0134 citations

Dose conversion between tapentadol immediate and extended release for low back pain.

2010-01-0124 citations